Novavax said on Tuesday it signed a licensing agreement allowing Pfizer access to its technology that boosts immune responses to vaccines for use in up to two infectious diseases, and the smaller company’s shares jumped nearly 7%.
Pfizer will gain access to Novavax’s Matrix-M adjuvant through the non-exclusive deal.
Sign up here.
Novavax will receive an upfront payment of $30 million in the first quarter of 2026. It will be eligible to receive up to an additional $500 million… [1804 chars]
Source: Reuters | Published: 2026-01-20T12:11:33Z
Credit: Reuters
